Literature DB >> 36177210

Can Preferentially Prescribing Angiotensin II Receptor Blockers (ARBs) over Angiotensin-Converting Enzyme Inhibitors (ACEIs) Decrease Dementia Risk and Improve Brain Health Equity?

Zachary A Marcum1, Jordana B Cohen2, Eric B Larson3, Jeff Williamson4, Adam P Bress5.   

Abstract

Entities:  

Year:  2022        PMID： 36177210      PMCID： PMC9499377          DOI： 10.31478/202205c

Source DB:  PubMed          Journal:  NAM Perspect        ISSN： 2578-6865


× No keyword cloud information.
  23 in total

Review 1.  Neuroprotective effects of angiotensin receptor blockers.

Authors:  Sonia Villapol; Juan M Saavedra
Journal:  Am J Hypertens       Date:  2014-10-31       Impact factor: 2.689

Review 2.  Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?

Authors:  Franz H Messerli; Sripal Bangalore; Chirag Bavishi; Stefano F Rimoldi
Journal:  J Am Coll Cardiol       Date:  2018-04-03       Impact factor: 24.094

Review 3.  Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics.

Authors:  B Afsar; R E Afsar; L A Ertuglu; M Kuwabara; A Ortiz; A Covic; M Kanbay
Journal:  Clin Transl Oncol       Date:  2020-09-15       Impact factor: 3.405

4.  The Value of Delaying Alzheimer's Disease Onset.

Authors:  Julie Zissimopoulos; Eileen Crimmins; Patricia St Clair
Journal:  Forum Health Econ Policy       Date:  2014-11-04

5.  2020 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2020-03-10       Impact factor: 21.566

6.  Improved blood pressure control associated with a large-scale hypertension program.

Authors:  Marc G Jaffe; Grace A Lee; Joseph D Young; Stephen Sidney; Alan S Go
Journal:  JAMA       Date:  2013-08-21       Impact factor: 56.272

7.  Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis.

Authors:  Diarmaid Hughes; Conor Judge; Robert Murphy; Elaine Loughlin; Maria Costello; William Whiteley; Jackie Bosch; Martin J O'Donnell; Michelle Canavan
Journal:  JAMA       Date:  2020-05-19       Impact factor: 56.272

8.  Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment.

Authors:  Zachary A Marcum; Jordana B Cohen; Chong Zhang; Catherine G Derington; Tom H Greene; Lama Ghazi; Jennifer S Herrick; Jordan B King; Alfred K Cheung; Nick Bryan; Mark A Supiano; Joshua A Sonnen; William S Weintraub; Jeff Williamson; Nicholas M Pajewski; Adam P Bress
Journal:  JAMA Netw Open       Date:  2022-01-04

9.  Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study.

Authors:  RuiJun Chen; Marc A Suchard; Harlan M Krumholz; Martijn J Schuemie; Steven Shea; Jon Duke; Nicole Pratt; Christian G Reich; David Madigan; Seng Chan You; Patrick B Ryan; George Hripcsak
Journal:  Hypertension       Date:  2021-07-26       Impact factor: 9.897

10.  Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial.

Authors:  Ihab Hajjar; Maureen Okafor; Darius McDaniel; Malik Obideen; Elizabeth Dee; Mahsa Shokouhi; Arshed A Quyyumi; Allan Levey; Felicia Goldstein
Journal:  JAMA Netw Open       Date:  2020-08-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.